YLYuanhua Lu

Yuanhua Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yuanhua Lu has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Chenchen Tang

    Biobank, Jilin Cancer Hospital, Changchun 130012, China

    1 shared publication
  • Chunjiao Wu

    Department of Medical Oncology Jilin Cancer Hospital Changchun China

    1 shared publication
  • Frank Wu

    TransThera Sciences (Nanjing). Inc. Fl 3, Bld 9, Phase 2 Accelerator Biotech and Pharmaceutical Valley, Jiangbei New Area Nanjing Jiangsu China

    1 shared publication
  • Hui Li

    Biobank Jilin Cancer Hospital Changchun China

    1 shared publication
  • Peiyan Zhao

    Medical Oncology Translational Research Lab Jilin Cancer Hospital Changchun China

    1 shared publication
  • Peng Peng

    TransThera Sciences (Nanjing). Inc. Fl 3, Bld 9, Phase 2 Accelerator Biotech and Pharmaceutical Valley, Jiangbei New Area Nanjing Jiangsu China

    1 shared publication

Latest Publications

  • Open Access

    Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT‐00420) Alone or With Chemotherapy Inhibit the Growth of SCLC

    by Hui Li, Chenchen Tang, Peiyan Zhao, Rui Zhong, Yuanhua Lu, Yan Liu, Rixin Li, Shaowei Lan, Chunjiao Wu, Xiaoyan Qiang, et al.

    There is an urgent need to develop new targeted treatment agents for small cell lung cancer (SCLC). Tinengotinib (TT‐00420) is a novel, multi‐targeted, and spectrally selective small‐molecule kinase inhibitor that has shown significant inhibitory effects on certain solid tumors in preclinical studies. However, its role and mechanism of action in SCLC remain unclear. In this study, we demonstrated that tinengotinib effectively inhibited SCLC cell proliferation, especially highly expressing NeuroD1 (SCLC‐N), in the SCLC cell line‐derived xenograft (CDX) model and the malignant pleural effusion cell model of patients with SCLC. When combined with etoposide/cisplatin, it synergistically inhibited SCLC growth. Tinengotinib regulates proliferation, apoptosis, migration, cell cycle and angiogenesis in SCLC cells. Mechanistic studies revealed that c‐Myc expression may be a key factor influencing the effect of tinengotinib in SCLC‐N. This study provides reliable preclinical data and a new direction for tinengotinib as a promising therapy for SCLC, either alone or in combination with chemotherapy.